RT Book, Section
A1 Fitzpatrick, Meghan E.
A1 Prendergast, Niall T.
A1 Rivera-Lebron, Belinda
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1186013107
T1 E-cigarette or vaping product-associated lung injury (EVALI)
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1186013107
RD 2024/04/24
AB An  outbreak  of  e-cigarette-  or  vaping  product–associated  lung  injury  (EVALI)  began  in  the  United  States  in  2019.  Approximately  66%  of  patients  have  been  male  and  80%  are  under  age  35.  Over  95%  of  reported  cases  required  hospitalization:  47%  were  admitted  to  intensive  care,  22%  were  intubated,  and  many  died.  Based  on  the  characteristics  of  these  patients,  the  diagnosis  of  EVALI  requires  reported  use  of  e-cigarette  or  vaping  products  within  3  months  of  symptom  onset,  compatible  chest  imaging  findings,  and  an  evaluation  that  excludes  infectious  etiologies.